Sign In
Buy VIR
$8.77
+0.0300 (+0.343%)
At Close: Jun 03, 2026
Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
04:05pm, Wednesday, 29'th May 2024
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer is scheduled to participate in a fireside chat
Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer
08:05am, Wednesday, 29'th May 2024
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Mark D. Eisner, M.D., M.P.H. will join the company as Executive Vice President and Chief Medical Officer (CMO
Vir Biotechnology to Host 2024 Annual Meeting of Stockholders
04:05pm, Thursday, 23'rd May 2024
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today reminds stockholders that it will hold its 2024 Annual Meeting of Stockholders on Wednesday, May 29, 2024, at 9:00 a.m. PT.
Multiple Abstracts Highlighting Vir Biotechnology's Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024
08:05am, Wednesday, 22'nd May 2024
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting new data from the Company's chronic hepatitis delta and chronic hepatitis B prog
Reser's Fine Foods Kicks Off 2024 ‘Good Times Tour'
08:00am, Wednesday, 22'nd May 2024
BEAVERTON, Ore.--(BUSINESS WIRE)-- #familyfestivals--Reser's Fine Foods kicks off 2024 ‘Good Times Tour' with free delicious samples and fun activities in their booth at festivals throughout 2024.
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the EASL Congress has changed the Company's Phase 2 SOLSTICE hepatitis delta presentation from a late-breaker post
DURHAM, N.C. and BEIJING, May 13, 2024 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient h
Wall Street Analysts Think Vir Biotechnology (VIR) Could Surge 188.65%: Read This Before Placing a Bet
11:01am, Tuesday, 07'th May 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 188.7% in Vir Biotechnology (VIR). While the effectiveness of this highly sought-after metric is questionable,
Vir Biotechnology, Inc. (VIR) Q1 2024 Earnings Call Transcript
12:35am, Friday, 03'rd May 2024
Vir Biotechnology, Inc. (NASDAQ:VIR ) Q1 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Sasha Damouni Ellis - Executive Vice President, Chief Corporate Affairs Officer Maria
Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Tops Revenue Estimates
07:06pm, Thursday, 02'nd May 2024
Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.99. This compares to loss of $1.06 per share a year ago.
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results
04:05pm, Thursday, 02'nd May 2024
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2024. “We are excited to
Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024
04:05pm, Tuesday, 30'th Apr 2024
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer is scheduled to participate in a fireside chat
What Makes Vir Biotechnology (VIR) a New Buy Stock
01:01pm, Wednesday, 24'th Apr 2024
Vir Biotechnology (VIR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D.
08:00am, Thursday, 18'th Apr 2024
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (“Vir” or “the Company”, Nasdaq: VIR) today announced the nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board
Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024
04:30pm, Thursday, 11'th Apr 2024
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter ended March 31, 202
